Discovery of Marinopyrrole A (Maritoclax) as a Selective Mcl-1 Antagonist that Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Discovery of Marinopyrrole A (Maritoclax) as a Selective Mcl-1 Antagonist that Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation
Authors
Keywords
-
Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 287, Issue 13, Pages 10224-10235
Publisher
American Society for Biochemistry & Molecular Biology (ASBMB)
Online
2012-02-07
DOI
10.1074/jbc.m111.334532
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacological Properties of the Marine Natural Product Marinopyrrole A against Methicillin-Resistant Staphylococcus aureus
- (2011) Nina M. Haste et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction
- (2011) Patricia Gomez-Bougie et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia
- (2011) A. Liao et al. BLOOD
- Targeting Mcl-1 for the therapy of cancer
- (2011) Bridget A Quinn et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Multiple BH3 Mimetics Antagonize Antiapoptotic MCL1 Protein by Inducing the Endoplasmic Reticulum Stress Response and Up-regulating BH3-only Protein NOXA
- (2011) Tina C. Albershardt et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Molecular dynamics study of small molecule inhibitors of the Bcl-2 family
- (2011) Stéphane Acoca et al. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
- Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
- (2010) D. Yecies et al. BLOOD
- The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib
- (2010) Hayato Hikita et al. HEPATOLOGY
- The BH3 α-Helical Mimic BH3-M6 Disrupts Bcl-XL, Bcl-2, and MCL-1 Protein-Protein Interactions with Bax, Bak, Bad, or Bim and Induces Apoptosis in a Bax- and Bim-dependent Manner
- (2010) Aslamuzzaman Kazi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Total Synthesis of (±)-Marinopyrrole A and Its Library as Potential Antibiotic and Anticancer Agents
- (2010) Chunwei Cheng et al. JOURNAL OF COMBINATORIAL CHEMISTRY
- ARC Synergizes with ABT-737 to Induce Apoptosis in Human Cancer Cells
- (2010) U. G. Bhat et al. MOLECULAR CANCER THERAPEUTICS
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer
- (2010) Michelle L Stewart et al. Nature Chemical Biology
- Simultaneous targeting ofMCL1andABCB1as a novel strategy to overcome drug resistance in human leukaemia
- (2009) Min Ji et al. BRITISH JOURNAL OF HAEMATOLOGY
- Marinopyrrole A Target Elucidation by Acyl Dye Transfer
- (2009) Chambers C. Hughes et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
- (2008) M Vogler et al. CELL DEATH AND DIFFERENTIATION
- Structure of the BH3 Domains from the p53-Inducible BH3-Only Proteins Noxa and Puma in Complex with Mcl-1
- (2008) Catherine L. Day et al. JOURNAL OF MOLECULAR BIOLOGY
- Bcl-XL-Templated Assembly of Its Own Protein−Protein Interaction Modulator from Fragments Decorated with Thio Acids and Sulfonyl Azides
- (2008) Xiangdong Hu et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Bcl-2 family proteins and cancer
- (2008) K W Yip et al. ONCOGENE
- The Marinopyrroles, Antibiotics of an Unprecedented Structure Class from a MarineStreptomycessp.
- (2008) Chambers C. Hughes et al. ORGANIC LETTERS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started